A multiple centers real-world study of regorafenib treatment modalities in Chinese metastatic colorectal cancer patients
Journal of Clinical Oncology
; 40(16), 2022.
Article
in English
| EMBASE | ID: covidwho-2005696
ABSTRACT
Background:
To evaluate the efficacy and safety of different treatment modalities of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC) in the real-world setting.Methods:
Individual patient data were retrieved from three leading oncology centers in China from January 2016 to March 2021. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS) and safety.Results:
The characteristics of patients who received treatment are shown in the table. Twenty-one patients received regorafenib combined with capecitabine as the second-line treatment for those who cannot visit hospital for their chemotherapies because of the COVID-19 pandemic. The median PFS and median OS were 8 (95% CI 4.36 -11.00) months and 26.9 (95%CI 20.54 -NR) months. 101 patients received regorafenib and 69 patients received regorafenib plus immune checkpoint inhibitor (ICIs) as third or higher line treatment, the overall response was 4.1%(7/170), including one complete response. Patients combined with ICIs have longer PFS than those with regorafenib monotherapy (median PFS = 3.3 versus 2.1 months;p = 0.01). Starting dose was 80, 120 and 160 mg in 64, 40 and 39 patients, respectively. Dose reduction was observed in 43.3% (39/79) of patients receiving 120 and 160 mg as the initial dose.Conclusions:
Different treatment modalities of regorafenib all showed promising efficacy and safety in the treatment of mCRC. Regorafenib combination is better than regorafenib monotherapy. Regorafenib combined with capecitabine provided a new treatment strategy during the epidemic but requires further investigation.
capecitabine; immune checkpoint inhibitor; regorafenib; adult; cancer chemotherapy; cancer combination chemotherapy; cancer patient; cancer survival; China; conference abstract; controlled study; coronavirus disease 2019; drug combination; drug safety; drug therapy; epidemic; female; human; major clinical study; male; metastatic colorectal cancer; monotherapy; multicenter study; overall survival; pandemic; patient coding; progression free survival; remission
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Journal of Clinical Oncology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS